Best Cancer Diagnosis Center: Understanding Prostate Cancer Diagnosis and Care

Prostate cancer diagnosis can be a complex process, and understanding the steps involved is crucial for patients and their families. Choosing the Best Cancer Diagnosis Center is a vital first step in ensuring accurate detection and effective management of this disease. This article provides a comprehensive overview of prostate cancer diagnosis, drawing on expert information to guide you through each stage, from initial screening to understanding your prognosis.

Prostate cancer is a significant health concern for men. Early and accurate diagnosis is key to successful treatment and improved outcomes. A leading cancer diagnosis center will offer a range of advanced diagnostic tools and expert specialists to ensure the most precise assessment of your condition.

Frequently Asked Questions About Prostate Cancer Diagnosis

To begin, let’s address some of the most common questions people have about prostate cancer diagnosis. These insights come from leading urologists and cancer specialists, providing reliable information to empower you in your healthcare journey.

How is the aggressiveness of my prostate cancer determined?

For men diagnosed with low to intermediate-risk prostate cancer, genomic tests can offer valuable insights into the cancer’s potential aggressiveness. These sophisticated tests analyze the DNA of your cancer cells, comparing them to those of other men to develop a personalized risk profile. While not 100% definitive, genomic testing provides the most evidence-based assessment of your specific prostate cancer’s characteristics. The best cancer diagnosis centers will have access to and expertise in interpreting these advanced genomic tests.

Can prostate cancer be sexually transmitted?

No, prostate cancer is not sexually transmitted. There is no risk to your partner through sexual activity. Prostate cancer is an internal condition and does not spread through physical contact.

Is prostate cancer hereditary?

Heredity can play a role in some prostate cancers. If you have been diagnosed with prostate cancer, your first-degree relatives – parents, siblings, or children – have an increased risk of developing the disease. If you are diagnosed at a younger age, such as in your 40s, genetic counseling may be recommended to identify any known genetic risk factors that you and your family might share. A comprehensive cancer diagnosis center will offer genetic counseling and testing as part of their services.

What lifestyle changes can help prevent or slow prostate cancer?

While there’s no guaranteed way to prevent prostate cancer, adopting a healthy lifestyle can be protective. Aim for at least 30 minutes of exercise daily, which has been shown to be beneficial. Diet also plays a crucial role. Limit red meat intake and focus on fresh fruits and vegetables, while minimizing sugars and carbohydrates. A heart-healthy diet is generally recommended, as research indicates it is also beneficial for prostate health. The best cancer diagnosis centers often provide nutritional counseling and lifestyle recommendations as part of a holistic approach to cancer care.

Does a prostate biopsy increase the risk of cancer spreading?

No, a prostate biopsy does not cause prostate cancer to spread. Millions of biopsies have been performed worldwide, and there has never been a documented case of cancer spreading as a result of this procedure.

At what age should prostate cancer screening be discontinued?

Not all prostate cancers are life-threatening, and not all require treatment. Generally, if your life expectancy is 10 years or less, prostate cancer is unlikely to significantly impact your lifespan. However, this is a personal decision that should be discussed with your healthcare team to determine the most appropriate screening plan for you. The best cancer diagnosis center will provide personalized screening recommendations based on your individual health profile and risk factors.

How can I effectively collaborate with my medical team during diagnosis and treatment?

Open and honest communication is key to being the best partner to your medical team. They are there to support you, provide resources, and assist you in every way possible. Never hesitate to ask questions or express concerns. Being well-informed is essential and makes a significant difference in your care. Patient-centered care and excellent communication are hallmarks of a top-tier cancer diagnosis center.

Prostate Cancer Diagnosis: Step-by-Step

Prostate cancer diagnosis usually begins with a physical exam and a blood test. These initial tests may be part of routine prostate cancer screening or prompted by symptoms you may be experiencing. If these initial tests raise concerns, imaging tests can provide detailed pictures of the prostate to look for signs of cancer. To confirm a diagnosis, a prostate biopsy, involving the removal of a small tissue sample for laboratory analysis, is typically necessary.

Prostate Cancer Screening

Prostate cancer screening aims to detect cancer in individuals who do not exhibit any symptoms. The common screening tests include the prostate-specific antigen (PSA) blood test and the digital rectal exam (DRE).

Most medical guidelines recommend that men begin discussing prostate cancer screening with their healthcare provider around age 50. This discussion allows for a shared decision-making process about whether screening is appropriate for you, considering your individual risk factors and preferences. Men who are Black, have a family history of prostate cancer, or have other risk factors might consider starting these discussions at a younger age. Seeking guidance from a best cancer diagnosis center can provide clarity on personalized screening strategies.

Digital Rectal Exam (DRE)

Digital Rectal Exam

A digital rectal exam is a procedure where a healthcare professional inserts a gloved and lubricated finger into the rectum to physically examine the prostate gland. The prostate is located near the rectum, allowing the healthcare provider to feel for any irregularities in the gland’s texture, shape, or size that might be concerning.

The DRE can be performed as part of routine prostate cancer screening or if symptoms suggest a potential prostate issue. It is a quick and simple procedure that provides valuable initial information about the prostate’s health.

During a DRE, the healthcare professional will gently insert a gloved, lubricated finger into the rectum. By feeling the prostate gland, they can assess its size, shape, and consistency, identifying any nodules, hardness, or other abnormalities that warrant further investigation.

Prostate-Specific Antigen (PSA) Test

The prostate-specific antigen (PSA) test is a blood test that measures the level of PSA in your blood. PSA is a protein produced by both normal and cancerous prostate cells, and a small amount of PSA circulates in the bloodstream. The PSA test detects and quantifies this PSA level in a blood sample.

Elevated PSA levels can be an indicator of prostate cancer. However, it’s important to note that high PSA levels can also be caused by other non-cancerous conditions, such as prostate enlargement (benign prostatic hyperplasia or BPH) or prostate infection (prostatitis). If an initial PSA test reveals an elevated level, it is typically repeated to confirm the finding. Your healthcare provider may recommend repeating the test within a few weeks to see if the PSA level decreases. If the level remains high or continues to rise, further diagnostic tests, such as imaging or a biopsy, may be necessary to determine if prostate cancer is present. A best cancer diagnosis center will utilize PSA testing in conjunction with other diagnostic tools for a comprehensive assessment.

The PSA test is commonly used for prostate cancer screening and may also be ordered if you are experiencing prostate cancer symptoms. The PSA test results, in combination with other factors, provide valuable clues to your healthcare provider in determining the next steps in diagnosis.

Prostate Ultrasound

Prostate ultrasound is an imaging technique that uses sound waves to create images of the prostate gland. This test may be recommended if a digital rectal exam reveals any abnormalities or if there is concern based on PSA levels.

To perform a prostate ultrasound, a healthcare professional inserts a thin probe into the rectum. This probe emits sound waves that bounce off the prostate gland, generating detailed images. This method, known as transrectal ultrasound (TRUS), allows for a clear visualization of the prostate.

Prostate MRI (Magnetic Resonance Imaging)

Magnetic resonance imaging (MRI) is a powerful imaging technique that utilizes magnetic fields and radio waves to produce detailed images of the body’s internal structures. A prostate MRI specifically focuses on generating images of the prostate gland. It is frequently used to identify suspicious areas within the prostate that could potentially be cancerous.

MRI images of the prostate can assist your healthcare team in deciding whether a prostate biopsy is necessary to obtain tissue samples for further examination. MRI can also guide biopsy procedures, particularly if concerning areas are identified. By targeting these areas, the biopsy can be more precise and effective. The advanced imaging capabilities of MRI are a key asset in a best cancer diagnosis center.

During a prostate MRI, you will lie on a table that slides into the MRI machine, which is typically a large, tube-shaped magnet. The magnetic field, combined with radio waves and the hydrogen atoms in your body, creates cross-sectional images of the prostate.

Several types of MRI techniques are used for prostate cancer diagnosis, including:

Contrast-enhanced MRI: This type of MRI uses a contrast dye, injected into a vein in your arm, to enhance the clarity of the images. The dye helps to highlight blood vessels and tissues, making abnormalities more visible.
MRI with endorectal coil: This technique involves inserting a small device called an endorectal coil into the rectum to obtain even more detailed images of the prostate. The coil, a thin wire, is inserted before the MRI and sends signals to the MRI machine, improving image quality.
Multiparametric MRI (mpMRI): Multiparametric MRI provides comprehensive information about the prostate tissue. It can differentiate between healthy tissue and cancerous tissue more effectively than standard MRI techniques. mpMRI is a valuable tool for detailed prostate assessment.

Prostate Biopsy

Transrectal Biopsy of the Prostate

A prostate biopsy is a procedure to remove a small sample of tissue from the prostate gland for microscopic examination in a laboratory. It is the definitive method for confirming the presence of prostate cancer.

A prostate biopsy involves using a needle to collect tissue samples. The needle can be inserted through the skin (perineal biopsy) or, more commonly, through the rectum (transrectal biopsy) to reach the prostate. Your healthcare team will determine the most appropriate biopsy type for your situation. Expertise in performing biopsies is crucial in a best cancer diagnosis center.

Types of prostate biopsy procedures include:

Transrectal Prostate Biopsy: This is the most common type of prostate biopsy. During this procedure, a thin probe is inserted into the rectum. This probe uses ultrasound imaging to guide the biopsy needle to specific areas of the prostate. The needle is then passed through the rectal wall into the prostate to collect tissue samples from various locations within the gland.
Perineal Prostate Biopsy: This less common approach involves inserting the biopsy needle through the perineum, the skin between the scrotum and the anus, to reach the prostate. Imaging guidance, often ultrasound, is used to ensure accurate needle placement and tissue sample collection from different areas of the prostate.

The collected prostate tissue samples are sent to a pathology lab for analysis. Pathologists examine the samples under a microscope to determine if cancer cells are present.

Prostate biopsies carry a small risk of bleeding, infection, blood in the urine (hematuria), and blood in the semen (hemospermia). Less commonly, biopsies can cause temporary difficulty urinating or infection. Side effects can vary depending on the biopsy type. It is important to discuss potential side effects and recovery expectations with your healthcare team.

Gleason Score and Grade Group

The Gleason score and grade group are systems used to assess the aggressiveness or grade of prostate cancer. These scores indicate how quickly the cancer is likely to grow and spread.

Pathologists, doctors specializing in diagnosing diseases through tissue analysis, examine prostate cancer cells from biopsy samples. They compare the appearance of cancer cells to normal prostate cells. Cancer cells that closely resemble healthy cells are considered low-grade and typically grow slowly. Cells that look very different from healthy cells are high-grade, indicating faster growth potential.

Prostate cancer grades range from 1 to 5, with Grade 1 being the lowest grade and Grade 5 the highest. To determine the Gleason score, pathologists identify the most prevalent grade of cancer cells in the biopsy samples and the second most prevalent grade. These two grades are added together to calculate the Gleason score.

Gleason scores range from 2 to 10. A score of 5 or lower is not considered indicative of cancer in this scoring system. Gleason scores from 6 to 10 indicate prostate cancer. A score of 6 suggests slow-growing cancer, while a score of 10 indicates rapidly growing cancer.

Prostate cancer grade is also reported as a grade group, which is another way to classify cancer aggressiveness. The grade groups are:

Grade Group 1: Gleason score of 6 or less.
Grade Group 2: Gleason score of 7, with the most common grade being 3 and the second most common being 4 (3+4=7).
Grade Group 3: Gleason score of 7, with the most common grade being 4 and the second most common being 3 (4+3=7).
Grade Group 4: Gleason score of 8 (typically 4+4=8).
Grade Group 5: Gleason score of 9 or 10 (e.g., 5+4=9 or 5+5=10).

Your healthcare team uses the grade group, along with other factors, to determine the stage of your prostate cancer and to guide treatment planning. The Gleason score and grade group are essential components of a comprehensive diagnosis provided by a best cancer diagnosis center.

Prostate Cancer Biomarker Tests

Biomarkers are measurable substances in the body that can provide information about health and disease. Biomarker tests for prostate cancer analyze specific biomarkers in cancer cells to gain deeper insights into the cancer’s characteristics and behavior.

Prostate cancer biomarker tests are used for several purposes:

To help decide if a prostate biopsy is needed: Some biomarker tests analyze blood or urine samples to detect signals associated with prostate cancer cells. These tests can help determine the likelihood of finding cancer in a biopsy, potentially avoiding unnecessary biopsies in some cases.
To guide treatment decisions for early prostate cancer: Certain biomarker tests assess the risk of early-stage prostate cancer spreading beyond the prostate. If initial tests are inconclusive, these biomarker tests can help clarify risk levels and guide decisions about whether to initiate immediate treatment or pursue active surveillance (close monitoring).
To inform treatment choices for advanced prostate cancer: For prostate cancer that has spread (metastasized), biomarker tests can help predict how the cancer cells might respond to specific treatments. These tests may analyze cells from the primary tumor or from metastatic sites, obtained through biopsy or blood samples (“liquid biopsy”).

Biomarker testing is not universally needed for all prostate cancer patients. These tests are continually evolving, and healthcare professionals are still refining their optimal use in clinical practice. A best cancer diagnosis center will be at the forefront of utilizing appropriate and beneficial biomarker tests.

Imaging Tests for Prostate Cancer Spread

Imaging tests are used to determine if prostate cancer has spread beyond the prostate gland to other parts of the body. This spread is known as metastasis. These tests can detect cancer in lymph nodes, bones, or other organs.

Most men with prostate cancer have localized disease, meaning the cancer is confined to the prostate. In these cases, imaging tests to check for spread may not be necessary. It’s important to discuss with your healthcare team whether such imaging is recommended for your specific situation.

When prostate cancer spreads beyond the prostate, it is referred to as metastatic prostate cancer, stage 4 prostate cancer, or advanced prostate cancer. Imaging tests used to detect spread include:

Bone Scan: A bone scan uses a radioactive tracer injected into the bloodstream. This tracer accumulates in areas of bone with increased metabolic activity, such as areas affected by cancer. A special camera detects the radioactivity and creates images of the bones, revealing potential sites of prostate cancer spread.
Computerized Tomography (CT) Scan: CT scans use X-rays to create detailed cross-sectional images of the body. CT scans can detect prostate cancer that has spread to lymph nodes or other organs in the abdomen and pelvis.
Magnetic Resonance Imaging (MRI): MRI can also be used to detect prostate cancer spread to lymph nodes or other soft tissues outside the prostate gland.
Positron Emission Tomography (PET) Scan: PET scans use a radioactive tracer, typically a glucose analog, that is injected into a vein. Cancer cells, which are often metabolically active, take up more of the tracer than normal cells. PET scans can identify areas of increased tracer uptake, indicating potential cancer spread.
Prostate-Specific Membrane Antigen (PSMA) PET Scan: PSMA PET scans are a newer type of PET scan that uses a tracer specifically designed to bind to PSMA, a protein found on the surface of most prostate cancer cells. PSMA PET scans are highly sensitive for detecting prostate cancer spread, even in small amounts, and are increasingly used in best cancer diagnosis centers.

Prostate Cancer Stages

Prostate cancer staging is a process used to describe the extent of the cancer, including its size, location, and whether it has spread. Staging is crucial for guiding treatment decisions and providing prognostic information.

Your healthcare team uses the results of diagnostic tests and procedures to determine the stage of your prostate cancer. The staging system considers several factors:

Extent of cancer in the prostate: How much of the prostate gland is affected by cancer.
Local spread: Whether the cancer has grown beyond the prostate into nearby tissues, such as the seminal vesicles, bladder, or rectum.
Lymph node involvement: Whether the cancer has spread to regional lymph nodes.
Distant metastasis: Whether the cancer has spread to distant parts of the body, such as bones or other organs.
PSA level: The level of prostate-specific antigen in the blood.
Grade group: The Gleason grade group, reflecting cancer aggressiveness.

Prostate cancer stages range from 1 to 4. Lower stages (1 and 2) indicate localized cancer confined to the prostate. Higher stages (3 and 4) indicate more advanced cancer, with stage 4 signifying metastatic disease. Generally, lower stages have a higher likelihood of cure. However, prognosis is influenced by multiple factors, and it is important to discuss your individual situation with your healthcare team.

The stages of prostate cancer are broadly defined as:

Stage 1 Prostate Cancer: Cancer is small, confined to one side of the prostate gland, PSA level is low, and grade group is 1.
Stage 2A Prostate Cancer: Cancer may be small and on one side but PSA is intermediate, or cancer is on both sides but PSA is low. Grade group is 1.
Stage 2B Prostate Cancer: Cancer is in the prostate, potentially on both sides, PSA is intermediate, and grade group is 2.
Stage 2C Prostate Cancer: Cancer is in the prostate, possibly on both sides, PSA is intermediate, and grade group is 3 or 4.
Stage 3A Prostate Cancer: Cancer is in the prostate, potentially on both sides, PSA is high, and grade group is 1 to 4.
Stage 3B Prostate Cancer: Cancer has extended beyond the prostate, possibly to seminal vesicles, bladder, or rectum. PSA level can be low, intermediate, or high, and grade group is 1 to 4.
Stage 3C Prostate Cancer: Cancer has a grade group of 5, regardless of size or local spread, but has not yet metastasized.
Stage 4A Prostate Cancer: Cancer has spread to regional lymph nodes.
Stage 4B Prostate Cancer: Cancer has spread to distant sites, such as bones or other organs.

Prostate Cancer Prognosis

Prognosis refers to the likely course of a disease and the chances of recovery. In prostate cancer, prognosis depends on various factors and is not solely determined by the stage. While stage provides a general outlook, your individual prognosis is more nuanced.

Factors that influence prostate cancer prognosis include:

Age: Younger men may have different prognoses than older men.
Overall health: Pre-existing health conditions can impact treatment options and outcomes.
Cancer stage: More advanced stages generally have a less favorable prognosis.
PSA level: Higher PSA levels at diagnosis may be associated with a less favorable prognosis.
Biopsy results: Gleason score and grade group are strong predictors of prognosis.
Treatment response: How the cancer responds to treatment is a crucial factor.

Discussing your prognosis with your healthcare team is essential for understanding your individual situation and setting realistic expectations. A best cancer diagnosis center will provide comprehensive prognostic assessments and personalized counseling.

Prostate Cancer Survival Rates

Survival rates provide statistical estimates of the percentage of people with a specific cancer who are alive for a certain period after diagnosis, typically five years. It’s important to remember that survival rates are population-based averages and cannot predict individual outcomes.

Prostate cancer survival rates are generally favorable, especially when the cancer is detected early and remains confined to the prostate.

Localized Prostate Cancer: When cancer is only in the prostate, the five-year survival rate is nearly 100%.
Regional Prostate Cancer: If cancer has spread to nearby tissues or lymph nodes, the five-year survival rate remains high, but slightly lower than for localized cancer.
Metastatic Prostate Cancer: When prostate cancer has spread to distant parts of the body (metastatic or stage 4), the five-year survival rate is approximately 37%.

It’s crucial to interpret survival statistics with caution. These data are based on patients diagnosed and treated in the past, and treatment advancements are continually improving outcomes. Prostate cancer death rates have been declining, and survival rates have been increasing over recent decades, reflecting progress in diagnosis and treatment. The best cancer diagnosis centers are driving forces in these advancements, offering cutting-edge diagnostic and therapeutic approaches.

Care at Mayo Clinic

Our caring team of Mayo Clinic experts can help you with your prostate cancer-related health concerns Start Here

More Information

Request an appointment

Treatment

Prostate cancer treatments are diverse and tailored to individual patient needs and cancer characteristics. Treatment options include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, targeted therapy, immunotherapy, and radiopharmaceutical therapy. The choice of treatment depends on factors such as cancer stage, grade, PSA level, patient health, and personal preferences. The best cancer diagnosis center will provide access to a full spectrum of treatment modalities and multidisciplinary expertise to develop the optimal treatment plan for you.

Active Surveillance for Prostate Cancer

Active surveillance, also known as watchful waiting, is a management strategy for certain low-risk prostate cancers. It involves close monitoring of the cancer through regular PSA tests, digital rectal exams, imaging, and repeat biopsies. Treatment is not initiated immediately but is reserved for if and when there are signs of cancer progression.

Active surveillance may be suitable for men with low-grade, slow-growing prostate cancer that is unlikely to cause harm in their lifetime, particularly for older men or those with significant co-existing health conditions. If monitoring indicates cancer growth or increased risk, treatment can be initiated.

Surgery for Prostate Cancer

Prostatectomy Incisions

Surgery to remove the prostate gland is called prostatectomy. It is a common treatment option for prostate cancer that is confined to the prostate. In some cases, it may also be used for locally advanced cancer or cancer that has spread to nearby lymph nodes.

Different surgical approaches for prostatectomy include:

Laparoscopic Prostatectomy: This minimally invasive technique involves making several small incisions in the abdomen through which surgical instruments and a camera are inserted. The surgeon uses these tools to remove the prostate gland.
Robotic Prostatectomy: This is a type of laparoscopic prostatectomy where the surgeon uses a robotic system to enhance precision and control. The surgeon controls robotic arms from a console to perform the surgery through small abdominal incisions. Robotic prostatectomy is now the most common surgical approach for prostate cancer. Best cancer diagnosis centers often have advanced robotic surgery programs.
Open Prostatectomy: This traditional approach involves a larger incision in the lower abdomen to directly access and remove the prostate gland. Open prostatectomy, also known as retropubic prostatectomy, is less common now but may be necessary in certain situations.

Prostatectomy carries risks such as bleeding, infection, pain, and blood clots. Minimally invasive approaches like laparoscopic and robotic prostatectomy tend to have lower risks of these complications. Long-term side effects can include urinary incontinence (leaking urine) and erectile dysfunction (difficulty getting erections), although these often improve over time.

External Beam Radiation Therapy for Prostate Cancer

External Beam Radiation for Prostate Cancer

External beam radiation therapy (EBRT) is a type of radiation therapy that uses a machine outside the body to deliver high-energy beams to target the prostate cancer. These beams can be X-rays, protons, or other types of energy.

During EBRT, you lie on a treatment table while a machine called a linear accelerator moves around you, delivering radiation from multiple angles to precisely target the prostate tumor while minimizing exposure to surrounding healthy tissues. Best cancer diagnosis centers utilize advanced radiation therapy technologies like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) for highly precise treatment delivery.

EBRT is typically given in daily fractions, five days a week, for several weeks. Shorter, more concentrated radiation schedules (hypofractionated radiation therapy) are also becoming increasingly common.

EBRT can be used to treat prostate cancer confined to the prostate, as well as locally advanced or metastatic disease. It may be used as the primary treatment or after surgery to eliminate any remaining cancer cells. In advanced cancer, EBRT can help slow cancer growth and alleviate symptoms like pain.

Side effects of EBRT can include bowel irritation (diarrhea, rectal bleeding), urinary symptoms (frequent or painful urination), and erectile dysfunction.

Brachytherapy for Prostate Cancer

Permanent Prostate Brachytherapy

Brachytherapy, also known as internal radiation therapy or seed implantation, involves placing radioactive sources directly into or near the prostate gland.

There are two main types of prostate brachytherapy:

Permanent Brachytherapy (Low-Dose Rate Brachytherapy): This involves implanting small, radioactive seeds, about the size of rice grains, directly into the prostate gland. These seeds emit a low dose of radiation over several weeks or months, gradually destroying cancer cells. The seeds remain permanently in the prostate but eventually become inactive.
Temporary Brachytherapy (High-Dose Rate Brachytherapy): This involves temporarily placing catheters into the prostate and inserting highly radioactive sources for short periods. The radioactive material is removed after each treatment session. Temporary brachytherapy may be repeated over several days.

Brachytherapy is typically used to treat prostate cancer that is confined to the prostate. It is not used for metastatic disease.

Side effects of brachytherapy can include urinary symptoms (frequent or painful urination, blood in urine), bowel problems (diarrhea, constipation), and erectile dysfunction.

Ablation Therapy for Prostate Cancer

Ablation therapies are minimally invasive techniques that use extreme temperatures to destroy cancer cells directly within the prostate. Ablation is not a standard treatment for all prostate cancers but may be used in select situations.

Types of ablation therapy for prostate cancer include:

Cryoablation (Cryotherapy): Cryoablation uses extreme cold to freeze and destroy prostate cancer cells. Thin needles are inserted through the perineum into the prostate, and very cold gas is passed through the needles to freeze the surrounding tissue. The tissue is then allowed to thaw, and this freeze-thaw cycle destroys cancer cells.
High-Intensity Focused Ultrasound (HIFU): HIFU uses focused sound waves to generate heat and destroy prostate cancer cells. A probe is inserted into the rectum to deliver high-intensity ultrasound waves to the prostate, heating the tissue to temperatures that kill cancer cells.

Ablation therapies may be considered for very small, localized prostate cancers, particularly when surgery or radiation therapy are not feasible due to other health conditions. Ablation may also be used to treat recurrent prostate cancer after radiation therapy.

Side effects of ablation can include pain, swelling, erectile dysfunction, and urinary problems.

Hormone Therapy for Prostate Cancer

Hormone therapy, also called androgen deprivation therapy (ADT), aims to reduce the levels of male hormones (androgens), such as testosterone, in the body. Prostate cancer cells rely on androgens to grow. Lowering androgen levels can slow cancer growth or cause cancer cells to die.

Hormone therapy approaches include:

Medications to stop testosterone production: Luteinizing hormone-releasing hormone (LHRH) agonists and antagonists are drugs that suppress the testicles’ production of testosterone. Examples include goserelin and degarelix.
Medications to block testosterone action: Antiandrogens are drugs that block testosterone from binding to and stimulating prostate cancer cells. Examples include bicalutamide and nilutamide.
Orchiectomy: Surgical removal of the testicles, which is a rapid way to reduce testosterone levels.

Hormone therapy is often used for advanced prostate cancer that has spread, to shrink tumors and slow growth. It may also be used in combination with radiation therapy for localized cancer to enhance radiation effectiveness.

Side effects of hormone therapy can include hot flashes, fatigue, loss of muscle mass, weight gain, decreased libido, erectile dysfunction, osteoporosis, and cardiovascular issues.

Chemotherapy for Prostate Cancer

Chemotherapy uses drugs to kill cancer cells throughout the body. It is typically used for advanced prostate cancer that has spread and is no longer responding to hormone therapy (castration-resistant prostate cancer).

Chemotherapy drugs commonly used for prostate cancer include docetaxel and cabazitaxel, administered intravenously. Chemotherapy is often given in cycles, typically every three weeks.

Side effects of chemotherapy can include fatigue, nausea, hair loss, increased risk of infection, and peripheral neuropathy (nerve damage causing numbness or tingling in hands and feet).

Targeted Therapy for Prostate Cancer

Targeted therapy drugs are designed to specifically attack cancer cells while minimizing harm to normal cells. They target specific molecules or pathways involved in cancer growth and progression.

For prostate cancer, targeted therapies may be used for advanced or metastatic castration-resistant prostate cancer. They are often used in combination with hormone therapy or other treatments.

Examples of targeted therapies for prostate cancer include PARP inhibitors (niraparib, olaparib, rucaparib, talazoparib), which target DNA repair mechanisms in cancer cells with specific genetic mutations. Genetic testing of the cancer cells is often necessary to determine if targeted therapy is appropriate. Best cancer diagnosis centers provide comprehensive genetic testing services.

Side effects of targeted therapies vary depending on the specific drug but can include fatigue, nausea, diarrhea, and blood count abnormalities.

Immunotherapy for Prostate Cancer

Immunotherapy harnesses the body’s immune system to fight cancer. It aims to stimulate the immune system to recognize and destroy cancer cells.

Immunotherapy approaches for prostate cancer include:

Cellular Immunotherapy (Sipuleucel-T): This personalized vaccine-like treatment involves collecting a patient’s immune cells, modifying them in the lab to recognize prostate cancer cells, and then infusing them back into the patient to boost the immune response against the cancer.
Immune Checkpoint Inhibitors (Pembrolizumab): These drugs block proteins called immune checkpoints that cancer cells use to evade the immune system. By blocking these checkpoints, checkpoint inhibitors can unleash the immune system to attack cancer cells. Checkpoint inhibitors are typically used for prostate cancers with specific genetic mutations (microsatellite instability-high or mismatch repair deficient).

Immunotherapy is generally used for advanced or metastatic prostate cancer.

Side effects of immunotherapy can vary but may include fatigue, skin rash, diarrhea, and, in rare cases, immune-related side effects affecting various organs.

Radiopharmaceutical Treatments for Prostate Cancer

Radiopharmaceutical treatments use radioactive drugs to deliver radiation directly to cancer cells. These drugs are often targeted to specific molecules on cancer cells or in the tumor environment.

Radiopharmaceuticals for prostate cancer are primarily used for advanced, metastatic castration-resistant prostate cancer.

Examples of radiopharmaceuticals for prostate cancer include:

PSMA-Targeted Radiopharmaceutical Therapy (Lutetium-177 vipivotide tetraxetan [Pluvicto]): This therapy targets prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. The drug consists of a molecule that binds to PSMA linked to a radioactive isotope (lutetium-177). After intravenous administration, the drug targets PSMA-positive prostate cancer cells throughout the body, delivering radiation directly to the cancer cells. Best cancer diagnosis centers are often leaders in offering PSMA-targeted radiopharmaceutical therapy.
Bone-Targeted Radiopharmaceutical Therapy (Radium-223 dichloride [Xofigo]): Radium-223 is a radioactive isotope that mimics calcium and is preferentially taken up by bone, particularly areas of bone metastasis from prostate cancer. It delivers radiation to bone metastases, helping to alleviate pain and improve survival in men with prostate cancer that has spread to the bones.

Side effects of radiopharmaceutical therapy vary but may include fatigue, nausea, dry mouth, and blood count abnormalities.

More Information

Request an appointment

Clinical Trials

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this condition.

Alternative Medicine

Complementary and alternative medicine (CAM) approaches are used alongside conventional medical treatments to manage symptoms and improve well-being. It is crucial to understand that CAM therapies are not a cure for prostate cancer, but they may help manage side effects and improve quality of life.

Many people with cancer experience distress, including anxiety, depression, and fatigue. CAM techniques may help cope with these challenges.

Examples of CAM therapies that may be helpful include:

Art therapy
Dance or movement therapy
Exercise
Meditation
Music therapy
Relaxation techniques
Spiritual practices

If you are considering CAM therapies, it is essential to discuss them with your healthcare team to ensure they are safe and appropriate for you and do not interfere with your conventional cancer treatments. A best cancer diagnosis center will often integrate supportive care services, including CAM therapies, to enhance patient well-being.

Coping and Support

Receiving a prostate cancer diagnosis can evoke a range of emotions, including disbelief, fear, anger, and sadness. Developing effective coping strategies is essential for navigating this journey.

Here are some coping mechanisms that may be helpful:

Become informed: Learn about your prostate cancer, treatment options, and what to expect. Knowledge empowers you to make informed decisions. Consult reliable sources and ask your healthcare team for recommendations.
Find a listener: Having someone to talk to about your feelings, fears, and hopes is invaluable. This could be a friend, family member, counselor, social worker, or clergy member.
Connect with other cancer survivors: Support groups and online communities of prostate cancer survivors offer unique peer support and understanding. Sharing experiences with others who have been through similar situations can be incredibly helpful.
Practice self-care: Prioritize your physical and emotional well-being. Eat a healthy diet, engage in regular exercise (as appropriate), and ensure you get enough sleep.
Maintain intimacy: If erectile dysfunction occurs, explore other forms of intimacy and closeness with your partner. Physical touch, emotional connection, and open communication remain vital aspects of a relationship.

Preparing for Your Appointment

If you have symptoms that concern you, schedule an appointment with your healthcare provider. If prostate cancer is suspected, you may be referred to a urologist (a doctor specializing in urinary tract conditions) or an oncologist (a cancer specialist). You may also consult with a radiation oncologist if radiation therapy is considered.

To make the most of your appointments, preparation is key.

What you can do:

Note any pre-appointment instructions: Ask if there are any dietary restrictions or other preparations needed before your appointment.
List your symptoms: Write down all symptoms you are experiencing, even if they seem unrelated to prostate concerns.
Gather personal information: Note any major life stresses or recent changes in your health.
Medication list: Compile a list of all medications, vitamins, and supplements you take.
Bring a companion: Having a family member or friend accompany you can be helpful for support and note-taking.
Prepare questions: Write down questions you want to ask your healthcare provider.

Questions to ask about prostate cancer:

Do I have prostate cancer?
What is the stage and grade of my prostate cancer?
Has the cancer spread?
What are my treatment options?
What are the benefits and risks of each treatment option?
What treatment approach do you recommend for me?
Do I need immediate treatment, or can I consider active surveillance?
What are the potential side effects of treatment?
What is my prognosis?
Are there any specialists I should consult?
Are there patient education materials or websites you recommend?

Do not hesitate to ask any other questions that are important to you during your appointment.

What to expect from your doctor:

Your healthcare team will ask about your symptoms, medical history, and family history. Be prepared to answer questions such as:

When did your symptoms begin?
Are your symptoms constant or intermittent?
How severe are your symptoms?
What factors make your symptoms better or worse?

By Mayo Clinic Staff

Prostate cancer care at Mayo Clinic

Request an appointment

Symptoms & causes Doctors & departments

Feb. 20, 2025

Prostate Cancer Discussions

Can anyone share their experience with Pluvicto? 131 Replies Wed, Mar 26, 2025

chevron-right

Stage 4 prostate cancer treatment options 141 Replies Tue, Mar 25, 2025

chevron-right

What is the average age of the gentlemen on here? 475 Replies Mon, Mar 24, 2025

chevron-right

See more discussions

DeVita VT Jr, et al., eds. Cancer of the prostate. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12th ed. Wolters Kluwer; 2023. Accessed Sept. 24, 2024.
Prostate cancer treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq. Accessed Sept. 24, 2024.
Prostate cancer early detection. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1460. Accessed Sept. 24, 2024.
Cancer stat facts: Prostate cancer. National Cancer Institute. https://seer.cancer.gov/statfacts/html/prost.html. Accessed Sept. 26, 2024.
Partin AW, et al., eds. Campbell-Walsh-Wein Urology. 12th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
Taplin M, et al. Clinical presentation and diagnosis of prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
Hematuria (blood in the urine). National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/urologic-diseases/hematuria-blood-urine. Accessed Oct. 7, 2024.
Niederhuber JE, et al., eds. Prostate cancer. In: Abeloff’s Clinical Oncology. 6th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
Sartor AO. Risk factors for prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
Sartor AO. Chemoprevention strategies in prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
Prostate cancer screening (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/prostate/patient/prostate-screening-pdq. Accessed Sept. 24, 2024.
AskMayoExpert. Prostate cancer: Screening (adult). Mayo Clinic; 2023.
Fowler GC, et al., eds. Prostate and seminal vesicle ultrasonography and biopsy. In: Pfenninger and Fowler’s Procedures for Primary Care. 4th ed. Elsevier; 2020. https://www.clinicalkey.com. Accessed Oct. 16, 2024.
Prostate MRI. RadiologyInfo.org. https://www.radiologyinfo.org/en/info/mr_prostate. Accessed Oct. 17, 2024.
Yang XJ. Interpretation of prostate biopsy. https://www.uptodate.com/contents/search. Accessed Oct. 16, 2024.
Biomarker testing for cancer treatment. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/biomarker-testing-cancer-treatment. Accessed Nov. 24, 2024.
Genomic diagnostic testing for prostate cancer. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/genomic-diagnostic-testing-for-prostate-cancer. Accessed Nov. 24, 2024.
Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Sept. 24, 2024.
Richie JP. Localized prostate cancer: Risk stratification and choice of initial treatment. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
Taplin M, et al. Initial staging and evaluation of males with newly diagnosed prostate cancer. https://www.uptodate.com/contents/search. Accessed Sept. 24, 2024.
American College of Surgeons. Prostate. In: AJCC Cancer Staging System. American College of Surgeons; 2023. https://online.statref.com. Accessed Aug. 1, 2024.
Population-based cancer survival statistics overview. National Cancer Institute. https://surveillance.cancer.gov/survival. Accessed Oct. 17, 2024.
Tepper JE, et al., eds. Prostate cancer. In: Gunderson & Tepper’s Clinical Radiation Oncology. 5th ed. Elsevier; 2021. https://www.clinicalkey.com. Accessed Sept. 24, 2024.
Pisters LL, et al. Cryotherapy and other ablative techniques for the initial treatment of prostate cancer. https://www.uptodate.com/contents/search. Accessed Nov. 24, 2024.
Murad V, et al. MR-guided focused ultrasound focal therapy for prostate cancer. Magnetic Resonance Imaging Clinics of North America. 2024; doi:10.1016/j.mric.2024.04.001.
Abida W, et al. Management of advanced prostate cancer with germline or somatic homologous recombination repair deficiency. https://www.uptodate.com/contents/search. Accessed Nov. 23, 2024.
Gulley J. Immunotherapy for castration-resistant prostate cancer. https://www.uptodate.com/contents/search. Accessed Nov. 23, 2024.
Immune checkpoint inhibitors. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. Accessed Nov. 23, 2024.
Dawson NA, et al. Overview of treatment for castration-resistant prostate cancer (CRPC). https://www.uptodate.com/contents/search. Accessed Nov. 24, 2024.
Distress management. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1431. Accessed Sept. 24, 2024.
Thompson RH, et al. Radical prostatectomy for octogenarians: How old is too old? The Journal of Urology. 2006; doi:10.1016/j.urology.2006.05.031.
Choline C-11 injection (prescribing information). Mayo Clinic PET Radiochemistry Facility; 2024. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed Nov. 24, 2024.
Woodrum DA, et al. Targeted prostate biopsy and MR-guided therapy for prostate cancer. Abdominal Radiology. 2016; doi:10.1007/s00261-016-0681-3.
Agarwal DK, et al. Initial experience with da Vinci single-port robot-assisted radical prostatectomies. European Urology. 2020; doi:10.1016/j.eururo.2019.04.001.
Gettman MT, et al. Current status of robotics in urologic laparoscopy. European Urology. 2003; doi:10.1016/S0302-2838(02)00579-1.
Krambeck AE, et al. Radical prostatectomy for prostatic adenocarcinoma: A matched comparison of open retropubic and robot-assisted techniques. BJU International. 2008; doi:10.1111/j.1464-410X.2008.08012.x.
What are radiopharmaceuticals? International Atomic Energy Agency. https://www.iaea.org/newscenter/news/what-are-radiopharmaceuticals. Accessed Nov. 24, 2024.

Frequently Asked Questions About Prostate Cancer Diagnosis

Prostate Cancer Diagnosis: Step-by-Step

Prostate Cancer Screening